CA2557151C - Analogues peptidiques de gip destines au traitement de diabetes, de la resistance a l'insuline et de l'obesite - Google Patents

Analogues peptidiques de gip destines au traitement de diabetes, de la resistance a l'insuline et de l'obesite Download PDF

Info

Publication number
CA2557151C
CA2557151C CA2557151A CA2557151A CA2557151C CA 2557151 C CA2557151 C CA 2557151C CA 2557151 A CA2557151 A CA 2557151A CA 2557151 A CA2557151 A CA 2557151A CA 2557151 C CA2557151 C CA 2557151C
Authority
CA
Canada
Prior art keywords
gip
insulin
glucose
mice
pro3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2557151A
Other languages
English (en)
Other versions
CA2557151A1 (fr
Inventor
Victor A. Gault
Finbarr Paul Mary O'harte
Peter Raymond Flatt
Nigel Irwin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ulster University
Original Assignee
Ulster University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ulster University filed Critical Ulster University
Publication of CA2557151A1 publication Critical patent/CA2557151A1/fr
Application granted granted Critical
Publication of CA2557151C publication Critical patent/CA2557151C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des analogues peptidiques qui sont des antagonistes du peptide inhibiteur gastrique (GIP). Les peptides, sur la base du GIP 1-42, comportent des substitutions et/ou des modifications qui améliorent la résistance à la dégradation par la dipeptidylpeptidase IV (DPP IV). L'invention concerne également un procédé de modification de la terminaison N de GIP ainsi que l'utilisation d'analogues peptidiques destinés au traitement de diabètes.
CA2557151A 2004-02-25 2005-02-25 Analogues peptidiques de gip destines au traitement de diabetes, de la resistance a l'insuline et de l'obesite Expired - Lifetime CA2557151C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0404124.0A GB0404124D0 (en) 2004-02-25 2004-02-25 Antagonists of GIP
GB0404124.0 2004-02-25
PCT/GB2005/000710 WO2005082928A2 (fr) 2004-02-25 2005-02-25 Analogues peptidiques de gip destines au traitement de diabetes, de la resistance a l'insuline et de l'obesite

Publications (2)

Publication Number Publication Date
CA2557151A1 CA2557151A1 (fr) 2005-09-09
CA2557151C true CA2557151C (fr) 2015-02-17

Family

ID=32050802

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2557151A Expired - Lifetime CA2557151C (fr) 2004-02-25 2005-02-25 Analogues peptidiques de gip destines au traitement de diabetes, de la resistance a l'insuline et de l'obesite

Country Status (6)

Country Link
EP (1) EP1730188A2 (fr)
JP (1) JP2008500280A (fr)
AU (1) AU2005217198A1 (fr)
CA (1) CA2557151C (fr)
GB (1) GB0404124D0 (fr)
WO (1) WO2005082928A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI770085B (zh) * 2017-11-21 2022-07-11 日商武田藥品工業股份有限公司 胜肽化合物

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005298689A1 (en) 2004-10-25 2006-05-04 Cytos Biotechnology Ag Gastric inhibitory polypeptide (GIP) antigen arrays and uses thereof
CA2622069A1 (fr) * 2005-09-08 2007-03-15 Uutech Limited Traitement de l'obesite associee aux diabetes
CA2623412A1 (fr) * 2005-09-08 2007-03-15 Uutech Limited Analogues de polypeptide inhibiteur gastrique comme traitement de la fonction reduite des cellules beta pancreatiques du fait du vieillissement
CA2913805A1 (fr) 2005-11-07 2007-05-18 Indiana University Research And Technology Corporation Analogues de glucagon a solubilite et a stabilite physiologiques ameliorees
WO2008021560A2 (fr) * 2006-08-17 2008-02-21 Amylin Pharmaceuticals, Inc. Analogue du gip et polypeptides hybrides possédant des propriétés sélectives
RU2477286C2 (ru) 2007-01-05 2013-03-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн АНАЛОГИ ГЛЮКАГОНА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ РАСТВОРИМОСТЬЮ В БУФЕРАХ С ФИЗИОЛОГИЧЕСКИМ ЗНАЧЕНИЕМ pH
CA2677932A1 (fr) 2007-02-15 2008-08-21 Indiana University Research And Technology Corporation Co-agonistes des recepteurs du glucagon/glp-1
GB0717388D0 (en) * 2007-09-07 2007-10-17 Uutech Ltd Use of GIP for the treatment of disorders associated with dysfunctional synaptic transmission
MX2010004298A (es) 2007-10-30 2010-05-03 Univ Indiana Res & Tech Corp Compuestos que exhiben actividad antagonista de glucagon y agonista de glp-1.
ES2509883T3 (es) 2007-10-30 2014-10-20 Indiana University Research And Technology Corporation Antagonistas de glucagón
US8710002B2 (en) * 2007-11-23 2014-04-29 Michael Rothkopf Methods of enhancing diabetes resolution
AR072160A1 (es) 2008-06-17 2010-08-11 Univ Indiana Res & Tech Corp Co-agonistas del receptor de glucagon/glp-1
CN102105159B (zh) 2008-06-17 2015-07-08 印第安纳大学研究及科技有限公司 基于gip的混合激动剂用于治疗代谢紊乱和肥胖症
US8450270B2 (en) 2008-06-17 2013-05-28 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers
GB0814068D0 (en) * 2008-08-01 2008-09-10 Univ Ulster Active immunisation against GIP
AU2009280021B2 (en) 2008-08-07 2012-10-04 Ipsen Pharma S.A.S. Analogues of glucose-dependent insulinotropic polypeptide (GIP) modified at N-terminal
ES2574835T3 (es) * 2008-08-07 2016-06-22 Ipsen Pharma S.A.S. Análogos del polipéptido insulinotrópico dependiente de glucosa
KR20110043687A (ko) 2008-08-07 2011-04-27 입센 파마 에스.에이.에스 포도당 의존적인 인슐린 분비 자극성 폴리펩타이드의 절단형 유사체
WO2010016940A2 (fr) * 2008-08-07 2010-02-11 Ipsen Pharma S.A.S. Analogues de polypeptide insulinotrope glucose-dépendant
PE20120332A1 (es) 2008-12-19 2012-04-14 Univ Indiana Res & Tech Corp Profarmacos de peptido de la superfamilia de glucagon basado en amida
JP5576694B2 (ja) * 2009-04-10 2014-08-20 花王株式会社 Ｇｉｐ上昇抑制剤
EP2443146B1 (fr) 2009-06-16 2016-10-05 Indiana University Research And Technology Corporation Composés de glucagon actifs sur le récepteur gip
US8703701B2 (en) 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
KR20120123443A (ko) 2010-01-27 2012-11-08 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 대사 장애 및 비만 치료용 글루카곤 길항제-ｇｉｐ 항진제 콘쥬게이트
MX2012013001A (es) 2010-05-13 2013-02-26 Univ Indiana Res & Tech Corp Peptidos de la superfamilia de glucagon que presentan actividad del receptor nuclear de hormonas.
JP6050746B2 (ja) 2010-05-13 2016-12-21 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation Ｇタンパク質共役受容体活性を示すグルカゴンスーパーファミリーのペプチド
US9023986B2 (en) 2010-10-25 2015-05-05 Hoffmann-La Roche Inc. Glucose-dependent insulinotropic peptide analogs
US8507428B2 (en) 2010-12-22 2013-08-13 Indiana University Research And Technology Corporation Glucagon analogs exhibiting GIP receptor activity
US9453062B2 (en) 2011-06-10 2016-09-27 Beijing Hanmi Pharmaceutical Co., Ltd. Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof
KR20140043793A (ko) 2011-06-22 2014-04-10 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 글루카곤/glp-1 수용체 공동-작용물질
RS56173B1 (sr) 2011-06-22 2017-11-30 Univ Indiana Res & Tech Corp Koagonisti receptora za glukagon/glp-1 receptora
JP6324315B2 (ja) 2011-11-17 2018-05-16 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ グルココルチコイド受容体の活性を示すグルカゴンスーパーファミリーのペプチド
CN104583232B (zh) 2012-06-21 2018-04-13 印第安纳大学研究及科技有限公司 展现gip受体活性的胰高血糖素类似物
KR102620911B1 (ko) 2014-10-29 2024-01-05 질랜드 파마 에이/에스 Gip 효능제 화합물 및 방법
JOP20190211A1 (ar) 2017-03-31 2019-09-15 Takeda Pharmaceuticals Co ببتيد منشط لمستقبل gip
KR102743887B1 (ko) * 2017-05-31 2024-12-19 유니버시티 오브 코펜하겐 장기-작용성 gip 펩타이드 유사체
US11633459B2 (en) 2018-05-04 2023-04-25 Novo Nordisk A/S GIP derivatives and uses thereof
SG11202105586YA (en) 2018-12-03 2021-06-29 Antag Therapeutics Aps Modified gip peptide analogues
CN113827706B (zh) * 2021-09-27 2023-12-26 南通大学 Gip及其衍生肽作为制备皮肤创伤治疗药物中的应用
TW202535912A (zh) * 2024-01-12 2025-09-16 大陸商杭州中美華東製藥有限公司 長效glp-1/gip雙激動劑的鼻腔遞送藥物組合物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6921748B1 (en) * 1999-03-29 2005-07-26 Uutech Limited Analogs of gastric inhibitory polypeptide and their use for treatment of diabetes

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI770085B (zh) * 2017-11-21 2022-07-11 日商武田藥品工業股份有限公司 胜肽化合物

Also Published As

Publication number Publication date
JP2008500280A (ja) 2008-01-10
WO2005082928A2 (fr) 2005-09-09
WO2005082928A3 (fr) 2005-12-01
AU2005217198A1 (en) 2005-09-09
EP1730188A2 (fr) 2006-12-13
CA2557151A1 (fr) 2005-09-09
GB0404124D0 (en) 2004-03-31

Similar Documents

Publication Publication Date Title
CA2557151C (fr) Analogues peptidiques de gip destines au traitement de diabetes, de la resistance a l'insuline et de l'obesite
US7875587B2 (en) Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
EP1171465B1 (fr) Analogues d'inhibiteur de peptide gastrique et leur utilisation dans le traitement du diabete
KR102622642B1 (ko) 인크레틴 유사체 및 그의 용도
JP7211712B2 (ja) グルカゴン受容体アゴニスト
KR102824306B1 (ko) 인크레틴 유사체 및 그의 용도
JP5485876B2 (ja) 代謝疾患の治療における治療剤としての非アシル化グレリン
US20090286722A1 (en) Analogs of Gastric Inhibitory Polypeptide as a Treatment for Age Related Decreased Pancreatic Beta Cell Function
US20090170762A1 (en) Treatment of Diabetes Related Obesity
CZ315594A3 (en) Peptide of glucagon type, insulinotropic derivatives, process of their preparation, pharmaceutical composition containing such compounds and use
KR102230368B1 (ko) 아실화 옥신토모듈린 펩타이드 유사체
KR101399178B1 (ko) 선별가능한 특성을 갖는 하이브리드 폴리펩티드
JP2023544959A (ja) 改善されたアミリン受容体（ｈＡＭＹ３Ｒ）効力を有するｈＡＭ１５－５２類似体
CN120603839A (zh) Nmu受体2激动剂
CN102781458A (zh) 多肽缀合物
AU2024377281A1 (en) Triple agonist compound
KR20250029046A (ko) 개선된 화학적 안정성을 갖는 아밀린 수용체(hAMY3R) 아고니스트

Legal Events

Date Code Title Description
EEER Examination request